Kymab Keeps Cash Coming In With $100m Led By Chinese Investors
Executive Summary
UK biotech Kymab and its Kymouse platform has added $100m to its cash pile with a Series C financing led by Chinese investors. It plans to enter the clinic next year with its first antibody therapeutic for graft-versus-host disease (GvHD).
You may also be interested in...
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.
VC Roundup: Flagship’s New Fund Designed To Raise Its Stake In Startups
Newly renamed Flagship Pioneering has raised a $285m venture capital fund to remain invested in portfolio companies as they grow. Also, 12 new and growing biopharma companies raised $657.15m.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.